Total Funding
93
66
Total FundingPost-IPO Equity raised
Growth Score 93 in past quarter
0 pts
Heat Score 66 in past quarter
0 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
109416
Imugene is a publicly-listed biotechnology company with operations in America and Europe,
- Paul Hopper: Executive DirectorPast Role: Polynoma, Founder
- Leslie Chong: CEOPast Role: Genentech, Sr. Clinical Program Leader
About the Company
Imugene is a clinical-stage immuno-oncology firm researching a variety of innovative medicines that aim to engage cancer patients' immune systems in order to find and eradicate tumors. OnCARlytics (CF33-CD19) is a novel and successful combination immunotherapy that uses the CF33 oncolytic virus to deliver and show CD19 antigen on the surface
of cancer cells, enabling CD19 CAR T cell anti-tumor responses against solid tumors.